Stoke Therapeutics, Inc. (STOK)
STOK moved a median of +0.27% 30 minutes after news, and +0.17% by the close. How STOK actually reacts to news — the realized, point-in-time move the market made, measured across 422 labeled events over the last three years with zero look-ahead.
STOK’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 45% | 421 |
| 30-min | +0.27% | 55% | 422 |
| 60-min | +0.10% | 51% | 422 |
| to close | +0.17% | 52% | 418 |
| Middle 50% of STOK reactions | -1.46% to +1.66% |
|---|---|
| Median reaction (30-min) | +0.27% |
| Measured reactions | 422 |
Half of all Stoke Therapeutics, Inc. news events land between -1.46% and +1.66% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How STOK reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 10 | +1.59% | 70% | -0.98% |
| Coverage initiations | 17 | -0.44% | 41% | +0.39% |
| Rating reiterations | 84 | -0.90% | 45% | -0.64% |
| Price-target raises | 17 | +0.75% | 53% | -0.06% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how STOK ranks against every other measured name →
That’s how STOK usually reacts — get an email when it moves on news →Email me when STOK moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to STOK's baseline. Nothing else.
Recent STOK events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Stoke Therapeutics, Inc. For: Sep 22 | SEC filing · Form 8-K | SEC EDGAR | -0.41% | +4.04% | |
| Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization | Press release | Business Wire | -0.67% | -3.07% | |
| Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | Press release | Business Wire | +1.62% | +1.83% | |
| Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) | Press release | Business Wire | +1.19% | +1.36% | |
| Stoke Therapeutics to Present at the Cantor Global Healthcare Conference | Press release | Business Wire | +1.94% | -3.05% | |
| Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) | Press release | Business Wire | +3.52% | +3.17% | |
| Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | Press release | Business Wire | +0.00% | +0.85% | |
| Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference | Press release | Business Wire | +2.01% | -0.31% | |
| Form 10-Q Stoke Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.45% | +10.04% | |
| Form 8-K Stoke Therapeutics, Inc. For: Aug 03 | SEC filing · Form 8-K | SEC EDGAR | +0.45% | +10.04% | |
| Form S-8 Stoke Therapeutics, Inc. | SEC filing · Form S-8 | SEC EDGAR | +0.45% | +10.04% | |
| Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates | Press release | Business Wire | +0.45% | +10.04% | |
| Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates | Press release | Business Wire | -1.03% | -0.94% | |
| Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | Press release | Business Wire | -0.28% | +0.76% | |
| Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer | Press release | Business Wire | -3.24% | -6.51% | |
| Form 8-K Stoke Therapeutics, Inc. For: Jun 30 | SEC filing · Form 8-K | SEC EDGAR | +0.30% | -0.55% | |
| Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome | Press release | Business Wire | +0.30% | -0.55% | |
| Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | Press release | Business Wire | +1.06% | +3.06% | |
| Form 8-K Stoke Therapeutics, Inc. For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | -1.29% | -0.43% | |
| Stoke Therapeutics to Present at Upcoming Investor Conferences in June | Press release | Business Wire | -1.10% | -3.19% | |
| Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | Press release | Business Wire | -1.50% | +4.75% | |
| Form 10-Q Stoke Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.52% | +3.04% | |
| Form 8-K Stoke Therapeutics, Inc. For: May 07 | SEC filing · Form 8-K | SEC EDGAR | +1.52% | +3.04% | |
| Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates | Press release | Business Wire | +1.52% | +3.04% | |
| Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates | Press release | Business Wire | +2.20% | +0.88% | |
| Form ARS Stoke Therapeutics, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.29% | -3.80% | |
| Form DEF 14A Stoke Therapeutics, Inc. For: Jun 03 | SEC filing · Form DEF | SEC EDGAR | -1.29% | -3.80% | |
| Form DEFA14A Stoke Therapeutics, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -1.29% | -3.80% | |
| Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | Press release | Business Wire | +0.86% | +3.18% | |
| Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference | Press release | Business Wire | -0.87% | +1.50% | |
| The Credibility Filter Wall Street Uses to Sort Biotech Winners | Press release | GlobeNewswire | +1.39% | +0.69% | |
| Form 8-K Stoke Therapeutics, Inc. For: Apr 03 | SEC filing · Form 8-K | SEC EDGAR | +1.39% | +0.69% | |
| Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors | Press release | Business Wire | +1.39% | +0.69% | |
| Form 8-K Stoke Therapeutics, Inc. For: Mar 23 | SEC filing · Form 8-K | SEC EDGAR | -2.06% | -3.73% | |
| Form S-3ASR Stoke Therapeutics, Inc. | SEC filing · Form S-3ASR | SEC EDGAR | -0.13% | +10.67% | |
| Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | Press release | Business Wire | -0.06% | -5.57% | |
| Form 10-K Stoke Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.55% | -0.06% | |
| Form S-8 Stoke Therapeutics, Inc. | SEC filing · Form S-8 | SEC EDGAR | +0.55% | -0.06% | |
| The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome | Press release | Business Wire | +0.56% | +2.73% | |
| Form 8-K Stoke Therapeutics, Inc. For: Feb 13 | SEC filing · Form 8-K | SEC EDGAR | -3.17% | +0.03% | |
| Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference | Press release | Business Wire | +2.10% | -0.50% | |
| Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | Press release | Business Wire | +0.93% | +11.70% | |
| Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA) | Press release | Business Wire | +0.12% | -0.83% | |
| Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 | Press release | Business Wire | +0.00% | -6.01% | |
| Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA | Press release | PR Newswire | +0.29% | +0.84% | |
| Form 8-K Stoke Therapeutics, Inc. For: Jan 21 | SEC filing · Form 8-K | SEC EDGAR | +2.46% | +0.89% | |
| Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | Press release | Business Wire | -1.25% | +2.57% | |
| Form 8-K Stoke Therapeutics, Inc. For: Jan 11 | SEC filing · Form 8-K | SEC EDGAR | -5.11% | +7.37% | |
| Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome | Press release | Business Wire | -5.11% | +7.37% | |
| Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | Business Wire | +2.32% | -1.87% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the STOK section they belong to.
Where else STOK is measured.
STOK earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Stoke Therapeutics, Inc.'s median reaction calculated?
Every labeled STOK news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 422 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 55% of STOK's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does STOK's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.